An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Tucatinib (Primary)
- Indications Breast cancer; Colorectal cancer
- Focus Pharmacokinetics
- Sponsors Seattle Genetics
- 16 May 2019 Status changed from recruiting to completed.
- 22 Jan 2019 Planned number of patients changed from 36 to 48.
- 02 Nov 2018 New trial record